Press Releases
Health Canada Grants Device License for iCAD’s ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
NASHUA, N.H., August 16, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada has issued a device license for ProFound Risk version 2.0, the latest version of iCAD’s personalized 1-2 year breast cancer risk assessment solution. …
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June…
iCAD and Google Health Expand Integration of Google’s AI Technology with iCAD’s ProFound Breast Health Suite for 2D Mammography for Use as Independent Reader
Worldwide commercialization agreement offers potential to ease radiologist workload and reduce healthcare disparities for women NASHUA, N.H., August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it signed an amendment to its development and commercialization agreement with…
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
NASHUA, N.H., July 31, 2023 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023. …
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
Agreement positions iCAD as Radiology Partners’ breast AI provider, expanding potential for iCAD’s technology to reach millions of women in the U.S. NASHUA, N.H., July 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a…
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD’s Breast AI Suite helps her detect the breast cancers radiologists fear most NASHUA, N.H., July 12, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound…
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting
Company’s ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities NASHUA, N.H., July 10, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it is showcasing its ProFound AI…
iCAD’s Breast AI Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomes NASHUA, N.H., May 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its Breast AI Suite…
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – May 15, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. Highlights:…
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published in Journal of Contemporary Brachytherapy NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced…